Responses
Regular and Young Investigator Award Abstracts
Biomarkers, Immune Monitoring and Novel Technologies
187 Immune checkpoint inhibitor (CPI) efficacy in gastrointestinal tumors with microsatellite-stable with high tumor mutational burden (MSS-TMB-H) compared to microsatellite instability-high (MSI-H)
Compose a Response to This Article
Other responses
No responses have been published for this article.
